David B Solit Selected Research

raf Kinases

7/2015	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
4/2014	Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
11/2013	Tumor adaptation and resistance to RAF inhibitors.
1/2013	Perturbation biology: inferring signaling networks in cellular systems.
12/2008	Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David B Solit Research Topics

Disease

173	Neoplasms (Cancer) 10/2022 - 02/2002
26	Melanoma (Melanoma, Malignant) 01/2022 - 05/2007
24	Carcinoma (Carcinomatosis) 05/2022 - 11/2003
16	Breast Neoplasms (Breast Cancer) 11/2021 - 02/2002
14	Lung Neoplasms (Lung Cancer) 01/2022 - 07/2006
14	Colorectal Neoplasms (Colorectal Cancer) 11/2021 - 07/2010
14	Neoplasm Metastasis (Metastasis) 10/2021 - 01/2008
14	Urinary Bladder Neoplasms (Bladder Cancer) 01/2021 - 10/2012
10	Adenocarcinoma 01/2022 - 11/2003
9	Disease Progression 01/2021 - 10/2003
7	Adenocarcinoma of Lung 01/2021 - 08/2007
7	Prostatic Neoplasms (Prostate Cancer) 11/2020 - 05/2002
6	Carcinogenesis 12/2017 - 01/2004
4	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2012
4	Microsatellite Instability 12/2019 - 01/2018
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 01/2008
3	Stomach Neoplasms (Stomach Cancer) 01/2020 - 11/2008
2	Inflammation (Inflammations) 10/2022 - 01/2021
2	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 10/2012
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021 - 10/2017
2	Non-Muscle Invasive Bladder Neoplasms 01/2021 - 12/2017
2	Brain Neoplasms (Brain Tumor) 12/2019 - 07/2015
2	Histiocytosis 12/2019 - 02/2016
2	Thrombocytopenia (Thrombopenia) 01/2018 - 12/2007
2	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 11/2016 - 07/2014
2	Colonic Neoplasms (Colon Cancer) 11/2016 - 12/2014
2	Leukemia 05/2014 - 12/2012

Drug/Important Bio-Agent (IBA)

30	Phosphotransferases (Kinase)IBA 01/2022 - 05/2003
30	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2008
27	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2021 - 12/2007
22	Biomarkers (Surrogate Marker)IBA 10/2022 - 04/2007
22	Pharmaceutical PreparationsIBA 01/2022 - 05/2002
18	Biological ProductsIBA 01/2022 - 01/2006
18	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2002
17	tanespimycin (17AAG)IBA 04/2012 - 02/2002
11	ErbB Receptors (EGF Receptor)IBA 01/2022 - 03/2005
10	PlatinumIBA 05/2021 - 01/2017
10	Mitogen-Activated Protein KinasesIBA 10/2018 - 12/2007
9	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 07/2014
9	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2018
8	Cell-Free Nucleic AcidsIBA 01/2021 - 01/2017
8	VemurafenibIBA 07/2015 - 07/2010
7	Trastuzumab (Herceptin)FDA Link 01/2022 - 12/2007
7	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2019 - 11/2008
7	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2015 - 12/2007
6	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 03/2009
5	neratinibIBA 10/2020 - 01/2017
5	Tyrosine Kinase InhibitorsIBA 10/2020 - 07/2006
5	raf KinasesIBA 07/2015 - 12/2008
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2009 - 05/2003
4	tyrosine receptor (receptor, tyrosine)IBA 01/2022 - 11/2008
4	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2018
4	Hormones (Hormone)IBA 01/2020 - 10/2003
4	Proto-Oncogene Proteins B-rafIBA 08/2014 - 08/2008
3	capivasertibIBA 01/2022 - 07/2017
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 01/2019
3	B7-H1 AntigenIBA 01/2021 - 01/2018
3	NVP-BKM120IBA 11/2020 - 01/2019
3	Formaldehyde (Formol)FDA Link 01/2020 - 08/2012
3	ParaffinIBA 01/2020 - 08/2012
3	AlpelisibIBA 01/2020 - 02/2015
3	human ERBB2 proteinIBA 12/2019 - 12/2007
3	Docetaxel (Taxotere)FDA Link 01/2019 - 03/2007
3	Estrogen ReceptorsIBA 10/2018 - 07/2017
3	LigandsIBA 01/2018 - 10/2003
3	AZD 6244IBA 12/2015 - 03/2010
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 12/2014 - 05/2003
3	Oncogene Proteins (Oncogene Protein)IBA 03/2013 - 01/2006
3	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 08/2012 - 12/2007
3	Cyclin D1IBA 09/2010 - 11/2008
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2010 - 05/2003
2	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2022 - 01/2012
2	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 05/2021 - 12/2020
2	Cyclin-Dependent Kinase Inhibitor p16IBA 01/2021 - 02/2015
2	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 01/2008
2	Protein Isoforms (Isoforms)IBA 01/2021 - 01/2019
2	RNA (Ribonucleic Acid)IBA 01/2021 - 09/2016
2	CateninsIBA 01/2021 - 09/2011
2	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 01/2019
2	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2018
2	Cytotoxins (Cytolysins)IBA 01/2020 - 08/2013
2	pembrolizumabIBA 01/2020 - 04/2019
2	AntibodiesIBA 01/2019 - 10/2018
2	ChromatinIBA 12/2017 - 02/2015
2	Adenosine Triphosphate (ATP)IBA 07/2017 - 01/2014
2	Monoclonal AntibodiesIBA 11/2016 - 09/2010
2	Cetuximab (Erbitux)FDA Link 11/2016 - 09/2010
2	Sorafenib (BAY 43-9006)FDA Link 02/2016 - 05/2007

Therapy/Procedure

78	Therapeutics 10/2022 - 01/2006
26	Drug Therapy (Chemotherapy) 10/2022 - 01/2008
10	Immunotherapy 01/2021 - 12/2017
9	Neoadjuvant Therapy 10/2022 - 01/2018
7	Castration 11/2020 - 05/2002
5	Cystectomy 10/2022 - 10/2014
3	Precision Medicine 10/2020 - 12/2015
2	Aftercare (After-Treatment) 01/2021 - 12/2014
2	Metastasectomy 01/2020 - 08/2014
2	Nephroureterectomy 01/2019 - 01/2016
2	Salvage Therapy 11/2016 - 02/2016
2	Radiotherapy 07/2015 - 12/2003